Successful treatment of resistant acromegaly with a growth hormone receptor antagonist

European Journal of Endocrinology

Volumn 145, Issue 4, 2001, Pages 451-456

  Drake, W M ^a   Parkinson, C ^a   Akker, S A ^a   Monson, J P ^a   Besser, G M ^a   Trainer, P J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE DERIVATIVE; GROWTH HORMONE RECEPTOR BLOCKING AGENT; OCTREOTIDE; PEGVISOMANT; RECEPTOR BLOCKING AGENT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID;

ACROMEGALY; ADULT; AGED; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS TUMOR; MALE; MEDICAL DOCUMENTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT; SOFT TISSUE; TUMOR VOLUME; WELLBEING;

EID: 0034815707     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1450451     Document Type: Article

References (29)

1. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure
2. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
3. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly
4. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience
5. Radiation therapy of acromegaly
6. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly
7. Treatment of acromegaly with dopamine agonists
8. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly
9. Cabergoline in the treatment of acromegaly: A study in 64 patients
10. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide
11. A prospective multicenter octreotide dose response study in the treatment of acromegaly
12. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study
13. Sandostatin LAR in acromegalic patients: Long-term treatment
14. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice
15. Rational design of potent antagonists to the human growth hormone receptor
16. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
17. A six-week, double blind, placebo controlled study of a growth hormone antagonist B2036-PEG (TrovertTM) in acromegalic patients
18. The Birmingham pituitary database: Auditing the outcome of the treatment of acromegaly
19. The outcome of surgery for acromegaly: The need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma
20. Conventional supervoltage irradiation is an effective treatment for acromegaly
21. How effective is external pituitary irradiation for growth hormone-secreting pituitary tumors?
22. Low-dose pituitary irradiation for acromegaly
23. Molecular biology of somatostatin receptors
24. Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas
25. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status
26. Long-acting growth hormones produced by conjugation with polyethylene glycol
27. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH
28. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs
29. An open-label study of a growth hormone receptor antagonist (pegvisomant) in the treatment of acromegaly